Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai, Merck to Start Lenvima Commercial Collaboration in Major Markets by March-End
Eisai CEO Haruo Naito said on November 1 that the company and US Merck will begin rolling out their commercial arrangements on the cancer drug Lenvima (lenvatinib) in major markets by the end of FY2018 under their strategic partnership pact…
To read the full story
Related Article
- Eisai’s 1st Half Operating Profit Zooms 74% on Lenvima Boon
November 2, 2018
- Eisai, MSD Begin Joint Information Provisioning for Lenvima in Japan
October 23, 2018
- Eisai Bags Up-to-US$5.76 Billion Lenvima Alliance with Merck
March 9, 2018
BUSINESS
- FDA Accepts BridgeBio’s Infigratinib NDA for Achondroplasia
October 8, 2026
- Eylea 8 mg Shows Vision Gains in 24-Week Analysis
October 8, 2026
- Boehringer, Hiroshima Tie Up on Health Promotion
October 8, 2026
- Japan Ethical Drug Sales Up 3% in August: Crecon
October 8, 2026
- PeptiDream Earns Milestone Payment from US Merck
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…